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Background: Epstein-Barr Virus (EBV) latently infects ~10% of gastric carcinomas (GC). Epstein-Barr Nuclear Antigen
1 (EBNA1) is expressed in EBV-associated GC, and can bind host DNA, where it may impact cellular gene regulation.
Here, we show that EBNA1 binds directly to DNA upstream of the divergently transcribed GC-specific tumor
suppressor genes gastrokine 1 (GKN1) and gastrokine 2 (GKN2).
Methods: We use ChIP-Seq, ChIP-qPCR, and EMSA to demonstrate that EBNA1 binds directly to the GKN1 and
GKN2 promoter locus. We generate AGS-EBV, and AGS-EBNA1 cell lines to study the effects of EBNA1 on GKN1 and
GKN2 mRNA expression with or without 5′ azacytidine treatment.
Results: We show that gastrokine genes are transcriptionally silenced by DNA methylation. We also show that
latent EBV infection further reduces GKN1 and GKN2 expression in AGS gastric carcinoma cells, and that siRNA
depletion of EBNA1 partially alleviates this repression. However, ectopic expression of EBNA1 slightly increased
GKN1 and GKN2 basal mRNA levels, but reduced their responsiveness to demethylating agent.
Conclusions: These findings demonstrate that EBNA1 binds to the divergent promoter of the GKN1 and GKN2
genes in GC cells, and suggest that EBNA1 contributes to the complex transcriptional and epigenetic deregulation
of the GKN1 and GKN2 tumor suppressor genes in EBV positive GC.
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Epstein-Barr virus (EBV) is a human gammaherpesvirus
found in a wide range of lymphoid and epithelial cell malig-
nancies, including Burkitt’s lymphoma, Hodgkin’s disease,
nasopharyngeal carcinoma (NPC), and post-transplant lym-
phoproliferative disease (reviewed in [1,2]). More recently,
EBV has been found in ~10% of all gastric carcinoma (GC)
cases worldwide [3,4]. EBV-associated GC has been shown
to be a monoclonal outgrowth of EBV-infected gastric epi-
thelial cells and is considered to be a distinct subtype of GC
[5,6]. Because the incidence of GC is close to 900,000
people per year [7], EBV-associated GC may be among the
most prevalent EBV-associated cancers.
In EBV positive gastric carcinoma cells, EBV establishes
a variant type I latency, where EBV transcription is limited* Correspondence: Lieberman@wistar.org
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stated.to the canonical type I genes EBNA1, EBERs, BART family
non-coding RNA and miRNAs, but with some additional
expression of LMP2A [6,8-11]. Among these latency
genes, EBNA1 is the only viral nuclear protein that is de-
tected in EBV-associated GC. EBNA1 is required for the
establishment of the latent episomal infection and for the
long-term survival of latently infected cells [12-15].
EBNA1 is a DNA binding protein that binds to both viral
and host chromosomal sites. The binding sites in the viral
genome have been characterized for essential functions in
replication and transcriptional control of viral gene expres-
sion. However, the function of EBNA1 sequence-specific
binding to the host chromosome is less well understood.
While EBNA1 can bind to the promoter regions of several
host genes, it remains unclear whether these genes are sub-
ject to EBNA1 regulation [12,16,17]. Overexpression of the
EBNA1 DNA binding domain, which functions as a dom-
inant negative in EBV infected cells, can inhibit cellThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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to and regulates cellular genes important for cell survival
[18]. Ectopic expression of EBNA1 has been shown to ef-
fect host cell mRNA expression [19], but it is not clear
whether these effects are direct or indirectly related to spe-
cific EBNA1 binding sites in the cellular genome.
In a previous study, we used ChIP-seq methods to
analyze the genome-wide enrichment sites of EBNA1 in
latently infected Raji Burkitt’s lymphoma cells and identi-
fied numerous cellular sites bound by EBNA1 [17].
Among those EBNA1 cellular enrichment sites we identi-
fied a significant EBNA1 binding peak located at the gas-
trokine 1 (GKN1) and gastrokine 2 (GKN2, also known as
trefoil factor interacting protein (TFIZ1)) gene cluster.
GKN1 and GKN2 have been identified based on their fre-
quent loss of expression in neoplastic gastric carcinoma
epithelial cells, compared to normal gastric tissue [20-22]
(reviewed in [23]). Several recent studies have described
anti-proliferative and anti-invasive activity for GKN1 in
gastric epithelial cells, which, together with its frequent
expression loss in cancer, suggests it functions as tumor
suppressor specific to gastric epithelium [21,24-28]. GKN1
can inhibit cell migration and invasion in wound healing,
transwell and Matrigel assay, as well as alter cell markers
associated with the epithelial-mesenchymal transition [26].
GKN1 and GKN2 genes are located in close proximity
and transcribed in opposite directions, suggesting that
they likely share a bi-directional promoter, and are subject
to coordinate regulation by shared transcription regulatory
factors (reviewed in [23]).
In this study, we demonstrated the direct binding be-
tween EBNA1 and GKN1-GKN2 loci and investigated
GKN1 and GKN2 gene expression modulation by EBV in-
fection and EBNA1 protein. Our findings suggest that
EBV infection can further inhibit GKN1 and GKN2 ex-
pression, and that loss of EBNA1 can facilitate epigenetic
de-repression of GKN2 transcription. We also observed
elevated DNA methylation levels at GKN1 and GKN2
promoter regions, and a potential role for EBNA1 in the
deregulation and epigenetic repression of this tumor sup-
pressor locus.
Results
Identification of a high-occupancy EBNA1 binding site at
GKN1-GKN2 locus by ChIP-Seq
Previously published ChIP-Seq data from Raji BL cells
revealed a limited number of highly enriched EBNA1
binding sites based on peak scores and read numbers
[17]. Further inspection revealed a strong EBNA1 bind-
ing site located upstream of the start sites for the diver-
gently transcribed GKN1 and GKN2 genes (Figure 1A,
upper track). A similar EBNA1 binding peak was ob-
served in a separate ChIP-Seq experiment performed in
EBV positive nasopharyngeal carcinoma cell line C666-1(full ChIP-seq data to be published elsewhere), indicat-
ing that this binding occurs in both epithelial, as well as
lymphoid cell types (Figure 1A, lower track). The center
of the peak was located ~ 5 kb from GKN2 and ~15 kb
from the GKN1 transcription start sites. ChIP-qPCR was
used to validate the EBNA1 binding at the GKN1-GKN2
promoter region in both Raji and C666-1 cells (Figure 1B
and C). qPCR indicated that EBNA1 bound to the GKN1-
2 site with similar efficiency to a previously validated
EBNA1-binding site at the PITPNB promoter. qPCR also
indicated that EBNA1 binding to GKN1-GKN2 was spe-
cific since there was no detectable EBNA1 binding at either
the cellular GAPDH locus or EBV OriLyt control regions,
as expected (Figure 1B and C). The putative EBNA1 bind-
ing site at GKN1-GKN2 locus was identified by alignment
with a consensus binding site in the EBV family of repeats
(FR) region, and this sequence was then tested for direct
binding to EBNA1 by EMSA (Figure 1D). Purified recom-
binant EBNA1 DBD protein was assayed for binding to
probes containing the GKN1-GKN2 site (GKN1/2), FR, or
a negative control sequence lacking a consensus EBNA1
binding site. We found that EBNA1 DBD bound efficiently
to the GKN1-GKN2 site, as well as to the FR consensus,
but did not bind to the control sequence. These findings
suggest that EBNA1 interacts with GKN1-GKN2 promoter
region through direct DNA-binding with the EBNA1 DBD.
GKN1 and GKN2 mRNA are highly expressed in primary
stomach tissue
We next measured GKN1 or GKN2 mRNA levels in vari-
ous gastric carcinoma cells lines and in primary normal
gastric tissue by qRT-PCR (Figure 2). We found that
GKN1 and GKN2 are expressed at much higher levels
(~3×104 fold) in primary stomach tissue than in any of the
cell lines tested (Figure 2A). Although at much lower
levels than primary stomach tissue, GKN1 and GKN2
were both expressed at measurable levels in AGS gastric
carcinoma cell lines, with GKN2 expressed at higher levels
than all other GC cell lines, or EBV positive B-cell or NPC
cell lines (Figure 2B). Very low levels of GKN1 or GKN2
could be detected in primary oral epithelial tissue, further
indicating that these genes are specific for primary gastric-
tissue.
EBV latency reduces GKN1 and GKN2 mRNA expression in
GC cell lines
To test the effect of EBV latent infection on GKN1 and
GKN2 expression, we generated an AGS cell line contain-
ing EBV B95.8 bacmid. The AGS cell line was selected for
hygromycin resistance and GFP positivity to ensure that it
contained bacmid components. To characterize the AGS-
EBV cell line, we first analyzed the EBV gene expression
pattern (Figure 3). We found that AGS-EBV cells expressed
detectable mRNA levels of EBNA1, BARF0, and LMP2A,
Figure 1 EBNA1 binds at the GKN1 and GKN2 promoter locus. (A) The UCSC genome browser was used to map EBNA1 binding peak
generated from Raji and C666-1 ChIP-seq at the GKN1 and GKN2 gene loci. RefSeq annotated transcripts are indicated below the ChIP-Seq peak.
(B-C) Realtime-PCR validation of ChIP-seq data for EBNA1 binding site at the GKN1/2 shared promoter region: EBNA1 (red bars) or control IgG
(blue bars) were assayed by ChIP in Raji (B) or C666-1 cells (C) for DNA binding at the GKN1/2 site, PITPNB promoter, GAPDH, or EBV Ori-Lyt. (D)
EMSA analysis of 32P labeled probes containing Control, GKN1/2 site, or EBV FR. Varying amount of EBNA1 DBD protein was used in binding
reaction (0, 100, 300, 900 ng). Arrowheads represent EBNA1-specific bound complexes or free probe as indicated. The probe sequence of GKN1/2
site and FR is indicated with sequence homolog (red letters) between GKN1/2 and FR. The negative control (Ctrl) sequence is also indicated.
Error bars indicate standard deviation from the mean (sdm) for n = 3.
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EBV B95.8 bacmid lacks the BART miRNAs, these findings
are consistent with AGS-EBV cells adopting a variant type I
latency gene expression program with some expression ofLMP2A, similar to that observed in EBV positive gastric
carcinoma tumor tissue [8,10]. To further characterize
AGS-EBV cells, we analyzed EBNA1 protein expression by
Western blot (Figure 4A) and EBV DNA copy number by
Figure 2 GKN1 and GKN2 mRNA are highly expressed in
primary stomach tissue. RT-PCR was performed to analyze the
mRNA level of GKN1 (blue bars) or GKN2 (red bars) in different cell
lines including GC-derived GTL, MKN28, MKN74, SNU638, AGS,
BL-derived Raji, EBV immortalized LCL, EBV positive NPC line C666-1,
or primary mouth epithelial cells comparing with (A) or without (B)
primary stomach tissue. Error bars indicate standard deviation from
the mean (sdm) for n = 3.
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abundance species at the expected molecular mass
(Figure 4A). EBV copy number was measured by com-
paring EBV Ori-Lyt DNA to cellular GAPDH (Figure 4B).
We found that AGS-EBV contained ~50% less copies of the
viral genome compared to EBV positive LCLs. To deter-
mine if EBNA1 retained its DNA binding activity in AGS-
EBV, we performed conventional ChIP assays (Figure 4C).
We found that EBNA1 bound to the EBV Dyad Symmetry
(DS) DNA, as well as to the GKN1-GKN2 binding site in
AGS-EBV cells. We next asked whether GKN1 or GKN2
mRNA levels were affected by EBV latent infection in AGS
cells by comparing RT-qPCR expression levels in AGS rela-
tive to AGS-EBV cells (Figure 4D). We found that GKN1
and GKN2 were repressed ~3-8 fold in AGS-EBV relative
to AGS cells, suggesting that EBV latency promotes or sta-
bilizes the transcriptional repression of GKN1 and GKN2.EBV increases DNA methylation dependent repression of
GKN1 and GKN2 mRNA in GC cell lines
GKN1 and GKN2 may be subject to epigenetic suppression
in GC and tissue culture cell lines. To explore this possibil-
ity, we tested whether treatment with DNA demethylating
agent 5′ azacytidine (Aza) or deacetylating agent (NaB)
combined with phorbol ester (TPA) would activate GKN1
or GKN2 in AGS cells (Figure 5A). We found that Aza
treatment led to a ~10 fold increase in GKN2, and ~ 4 fold
increase in GKN1 transcription in AGS treated cells. In
contrast, NaB/TPA treatment produced only ~2 fold activa-
tion of transcription. These findings suggest that both
GKN1 and GKN1 are under active epigenetic repression
through DNA methylation. To test if EBV had any effect
on Aza induced activation of GKN1 or GKN2, we com-
pared the effects of Aza treatment on AGS relative to
AGS-EBV cells by qRT-PCR (Figure 5B). We found that
GKN1 and GKN2 were efficiently activated by Aza treat-
ment in AGS cells, but to a lesser extent in AGS-EBV. In
these experiments, Aza-induced activation of GKN2 was
completely eliminated, while activation of GKN1 was only
partly attenuated. Aza-treatment also led to the ~8.4 fold
increase in EBNA1 mRNA levels, suggesting that Aza treat-
ment stimulates EBV lytic gene expression in AGS-EBV cell
lines. These results suggest the EBV gene products prevent
GKN2, and to a lesser extent GKN1 activation after Aza
treatment.
To better understand the mechanism of GKN1 and
GKN2 epigenetic repression, we examined the DNA
methylation levels using methyl cytosine-specific antibody
directed DNA immunoprecipitation (MeDIP) assay. We
assayed the enrichment of methylated DNA in the GKN1-
GKN2 control region in AGS and AGS-EBV cells with or
without Aza treatment (Figure 5C). We observed a relative
enrichment of methylated CpG at a region between the
EBNA1 binding site and GKN2 transcription start site
(GKN2_A). Aza treatment led to a decrease in MeDIP sig-
nal in most regions where a signal was detected, suggest-
ing that Aza treatment led to a general reduction in DNA
methylation. Similar loss of CpG methylation was ob-
served at the alpha-globin gene (which does not bind
EBNA1), and at several EBNA1 binding sites, including
HDAC3 and MAP3K7IP (Figure 5D). We also noted that
MeDIP signals were generally higher in EBV-AGS than in
AGS cells, suggesting that EBV latent infection may pro-
mote or stabilize DNA methylation throughout the host
genome.
EBNA1 depletion activates GNK1 and GKN2 mRNA
expression in EBV positive epithelial cells
To determine if EBNA1 contributed to the transcriptional
repression of GKN1 and GKN2, we first attempted to de-
plete EBNA1 in AGS-EBV cells using siRNA (Figure 6).
We generated a siRNA targeting the 3′ non-coding UTR
Figure 3 Characterization of EBV gene expression in AGS-EBV cell lines. AGS, AGS-EBV positive, and EBV-LCLs were assayed for mRNA
expression by qRT-PCR with primers for EBNA1, BARF0, LMP2A, LMP1, EBNA2, or EBNA3C, as indicated. Error bars indicate standard deviation from
the mean (sdm) for n = 3.
Figure 4 EBV infection of AGS cells suppresses GKN1 and GKN2 transcription. (A) Western blot analysis of EBNA1 protein expression in
AGS-EBV cells compared with EBV-negative AGS cells was performed using antibody for EBNA1 (top) or Actin (bottom). (B) DNA copy number
was assayed by real-time PCR of EBV Ori-Lyt DNA relative to the level of cellular GAPDH in AGS, AGS-EBV, and EBV-LCL cells. (C) ChIP and
real-time PCR analysis of EBNA1 (red bars) or control IgG (blue bars) for DNA binding at the EBV sites including DS and Ori-Lyt, or cellular sites
including GKN1/2 and GAPDH in AGS-EBV cells. (D) RT-PCR was performed to analyze the mRNA level of GKN1 or GKN2 in AGS (blue bars) or
AGS-EBV cells (red bars). ** indicates p < .005. Error bars indicate standard deviation from the mean (sdm) for n = 3.
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Figure 5 EBV reinforces the repression of GKN1 and GKN2 gene expression by DNA methylation. (A) AGS cells were treated with 10 μM
Aza, or 1 mM NaB and 20 ng/mL TPA for 48 hours and analyzed by RT-PCR for GKN1 or GKN2 expression level, compared with untreated AGS.
(B) AGS cells or AGS-EBV cells were treated or untreated with 10 μM Aza for 48 hours, then assayed for GKN1, GKN2 mRNA, or EBNA1 mRNA
levels. (C) MeDIP assay of AGS or AGS-EBV cells treated or untreated with 10 μM Aza for 48 hours at different DNA regions of GKN1 and GKN2
loci. (D) MeDIP assay of AGS or AGS-EBV cells treated or untreated with 10 μM Aza for 48 hrs at cellular regions for alpha globin-2, GAPDH, CDC7,
FOXP2, HDAC3, or MAP3KIP2. (E) Genome position of primers used for GKN1-GKN2 ChIP and MeDIP assays. * indicates p < .05, ** indicates p < .005.
Error bars indicated sdm for n = 3.
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tein in AGS-EBV cells (Figure 6B). Depletion of EBNA1
resulted in an ~5 fold activation of GKN2, with littledetectable activation of GKN1 (Figure 6A). These findings
suggest that EBNA1 may function as a transcriptional re-
pressor of GKN2 in AGS-EBV cells.
Figure 6 siRNA depletion of EBNA1 causes de-repression of the
GKN1 and GKN2 in AGS-EBV cells. siCtrl or siEBNA1 transfected
AGS-EBV cells were assayed by RT-PCR for GKN1 or GKN2 mRNA
level relative to cellular GAPDH (A). Cells were harvested at 72 hours
post-transfection with siRNA. Western blot showing EBNA1 (top
panel) and loading control Actin (lower panel) in AGS-EBV cells (B).
Error bars indicate standard deviation from the mean (sdm) for n = 3.
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demethylation
To further explore the contribution of EBNA1 to GKN1
and GKN2 transcription regulation, we tested the effect
of ectopic expression of EBNA1 alone on Aza-induced
levels of GKN1 or GKN2 transcription in GC cells. AGS
cells were transduced with an EBNA1 expressing lenti-
virus. Stable AGS-EBNA1 (pLU-EBNA1) or AGS- con-
trol vector (pLU-Vec) cell lines were selected and
assayed for GKN1 and GKN2 mRNA levels. We ob-
served that AGS-EBNA1 cells had a ~2-3 fold higher
basal level of GKN1 and GKN2 mRNA relative to paren-
tal AGS cells (Figure 7A). However, Aza-induced mRNA
levels of GKN1 and GKN2 were attenuated in AGS-
EBNA1 compared to AGS cells (Figure 7B). Aza treat-
ment also led to a large increase in EBNA1 mRNA levels
(Figure 7C). To determine if the effects of EBNA1 on
GKN1 and GKN2 were specific to AGS cells, we trans-
duced another EBV negative GC cell line MKN74 withEBNA1 lentivirus (Figure 7D-F). Similar to AGS cells,
we found that EBNA1 increased basal levels of GKN1
and GKN2, but inhibited the ability of Aza to further in-
duce GKN1 and GKN2 mRNA levels (Figure 7D and E).
We confirmed that Aza-treatment was effective by
measuring EBNA1 mRNA levels, which increased ~7
fold (Figure 7F). These findings suggest that ectopic ex-
pression of EBNA1 can increase basal, but inhibit Aza-
induced levels of GKN1 and GKN2 transcription in
EBV-negative GC cell lines.
Discussion
In this study, we identified a high-occupancy EBNA1
binding site in the 5′ promoter control region of the diver-
gently transcribed GKN1 and GKN2 genes. EBNA1 bind-
ing sites were observed in two independent ChIP-Seq data
sets from EBV positive lymphoid BL cells Raji and EBV
positive epithelial nasopharyngeal carcinoma cells C666-1
(Figure 1A). We confirmed these binding sites by conven-
tional ChIP–qPCR in both cell lines (Figure 1B and C).
EBNA1 was also shown to bind directly to these sites by
EMSA with purified recombinant EBNA1 DBD protein
(Figure 1D). We show that GKN1 and GKN2 mRNA
levels are highly repressed in most cell lines relative to pri-
mary gastric tissue (Figure 2). To study the potential role
of EBV and EBNA1 in the transcriptional control of
GKN1 and GKN2, we generated an EBV positive AGS
gastric carcinoma cell line. We show that EBV adopts a
variant type I latency pattern in AGS cells (Figure 3), and
that EBNA1 can bind to the GKN1/GKN2 promoter re-
gion in the cellular chromosome (Figure 4C). We also
found that GKN1 and GKN2 mRNA were further sup-
pressed in EBV positive AGS cells relative to control EBV
negative AGS cells (Figure 4D). We then showed that
Aza-treatment led to the increase expression of GKN1
and GKN2 (Figure 5A), and that EBV latent infection in-
hibits Aza activation of GKN2 (Figure 5B). We found that
siRNA depletion of EBNA1 in EBV positive AGS cells
leads to transcription activation of GKN2 (Figure 6). We
also show that EBNA1 ectopic expression moderately in-
creases basal, but inhibits the Aza-induced levels of GKN1
and GKN2 transcription (Figure 7). Taken together, these
findings indicate that EBNA1 binds to the GKN1-GKN2
promoter control region in multiple cell types, and raise
the possibility that EBNA1 contributes to the transcrip-
tional and epigenetic repression of the GKN1 and GKN2
tumor suppressor genes in EBV positive GC.
EBV latent infection is known to increase the tumori-
genic phenotype of gastric carcinoma cells [29-31]. GKN1
and GKN2 are reported to function as cell growth inhibi-
tors and tumor suppressors in GC [20,21,23,25-27]. Our
mRNA expression data showing high-level mRNA expres-
sion only in primary normal gastric tissue are consistent
with a role of GKN1 and GKN2 as a tumor suppressor.
Figure 7 EBNA1 inhibits GKN1 and GKN2 transcription after DNA demethylation in GC cells. (A) AGS cells were transduced with pLU-Vector
(Vec) or pLU-EBNA1 and then untreated (Untr) or treated with 10 μM 5′-azacytidine (Aza) for 48 hrs. GKN1 and GKN2 mRNA were quantified by
qRT-PCR relative to GAPDH. (B) Fold induction of GKN1 and GKN2 mRNA by Aza were quantified from panel A. (C) qRT-PCR analysis of EBNA1 mRNA
levels in AGS cells. (D) Same as in A, except for using MKN74 rather than AGS cells. (E) Fold induction of GKN1 and GKN2 mRNA quantified from panel
D. (F) qRT-PCR analysis of EBNA1 mRNA levels in MKN74 cells. *indicates p < .05, **indicates p < .005. Error bars indicated sdm for n = 3.
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either or both GKN1 or GKN2 in AGS or AGS-EBV cause
a cell cycle arrest or reduce viability (data not shown).
This suggests that GKN1 and GKN2 function at earlier
stages in tumor cell evolution, or in more complex tumor
microenvironments. We speculate that EBNA1 may have
a more pronounced effect on GKN1 and GKN2 expres-
sion in situations where EBV may infect primary gastric
cells where basal expression of GKN1 and GKN2 are high
and important for tumor suppression.
Previous published studies have shown that GKN1
and GKN2 transcription is subject to epigenetic sup-
pression by DNA methylation in all forms of GC [21].
Our studies are consistent with the role of DNA methy-
lation in the epigenetic suppression of GKN1 and
GKN2 in AGS cells. Treatment with Aza resulted in the
4-10 fold increase in GKN1 and GKN2 mRNA expres-
sion (Figure 5A), and MeDIP revealed enrichment ofmethylated DNA at the promoter regions (Figure 5C).
AGS-EBV cells did show an increase in DNA methylation
at several cellular sites, including regions surrounding
the EBNA1 binding sites at the GKN1 promoter region
(Figure 5C), and the HDAC3 and MAP3K7IP2 genes
(Figure 5D). However, the presence of EBNA1 in AGS-EBV
cells did not prevent Aza-induced demethylation at these
sites. This suggests that EBNA1 may repress transcription
from some promoters, like GKN2, through a mechanism
distinct from DNA methylation. However, ectopic expres-
sion of EBNA1 alone produced a more complicated pheno-
type, causing a small increase in basal expression, but
limiting the effects of Aza-induced demethylation (Figure 7).
This may suggest that that EBNA1 may function differently
when expressed ectopically, than when expressed in the
context of the viral genome. Nevertheless, our findings sug-
gest that EBNA1 perturbs the normal transcriptional regu-
lation of the GKN1 and GKN2 genes.
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lation remains unclear. EBNA1 has been implicated in
the transcriptional activation and repression of both viral
and cellular genes [32,33]. EBNA1 can repress its own
mRNA expression from the EBV Qp in type III latency,
where repression has been linked to steric interference
with RNA polymerase II binding to the transcription ini-
tiation site [34]. On the other hand, EBNA1 can activate
Cp and LMP1 promoters in type III latency where it
may function as an enhancer-like factor [35-37]. EBNA1
has been implicated in transcription activation of some
cellular genes, including the Nox2 gene involved in re-
active oxygen species formation [19]. EBNA1 may also
affect host-cell transcription through a global remodel-
ing of the host chromosome [38]. Thus, EBNA1 may
alter cellular transcription through multiple direct and
indirect mechanisms.
Epigenetic modifications are known to play an important
role in EBV-associated gastric carcinoma [39]. Interestingly,
AGS cells carrying EBV bacmid genomes had higher levels
of methylated DNA at many tested sites (Figure 5D). This
is consistent with the proposed role of EBV in the methyla-
tion of host tumor suppressor genes [40]. This is also con-
sistent with the findings that EBV positive GC has elevated
DNA methylation at promoter regions of several key GC
tumor suppressors, including gastrokine genes [39,41-45].
While EBNA1 bound near DNA methylated regions of the
GKN2, we were unable to show that EBNA1 modulates
DNA methylation at the GKN1 and GKN2 sites (data not
shown). However, it is possible that EBNA1 in association
with another viral encoded or induced factor may stabilize
GKN1 and GKN2 transcriptional repression through a
chromatin-dependent and structural mechanism that rein-
forces DNA methylation. It is also possible that EBNA1
may regulate GKN1 or GNK2 only in tissue or tumor mi-
croenvironments that are not readily recapitulated in cell
culture. While the function of EBNA1 binding to host cell
chromosome sites remains an important area of investiga-
tion, more sophisticated infection models may be required
to elucidate its potential role in altering host cell gene ex-
pression and carcinogenesis.
Methods
Cells, plasmids, and lentivirus infection
EBV-positive Burkitt’s lymphoma Raji cells, EBV posi-
tive nasopharyngeal carcinoma C666-1 cells, and gastric
carcinoma cell lines (a gift from Dr. Antonia R. Sepulveda,
Columbia University) including GTL, MKN28, MKN74,
SNU638 were maintained in RPMI containing 10%
FBS and supplemented with antibiotics (penicillin and
streptomycin). Gastric carcinoma AGS cells (ATCC No.
CRL-1739) were maintained in F-12K containing 10%
FBS. Primary mouth epithelial cells were provided by Dr.
Manjunatha Benakanakere, University of Pennsylvania andcultured in Keratinocyte-SFM medium. EBV-LCL was
established by primary infection of peripheral blood
mononuclear cells (PBMC) with EBV BAC virions gener-
ated from stimulated 293-EBV cells [46,47]. EBV-LCL
contains a hygromycin B resistant EBV bacmid were
maintained in RPMI containing 10% FBS, hygromycin B
(100 μg/ml), glutamax (Invitrogen), and antibiotics. AGS-
EBV cells were generated from AGS cells co-cultivated
with EBV-LCL by adapting a previously published co-
cultivation method described AGS cells infection with
rEBV through cell-to-cell contact [48] with some modifi-
cation. Briefly, EBV-LCL was induced by 20 ng/mL 12-O-
tetradecanoylphorbol-13-acetate (TPA) and 1 mM sodium
butyrate (NaB) 24 hours prior to co-cultivation. The in-
duced EBV-LCL cells were washed with PBS twice to
completely remove the inducing agents, resuspended with
complete RPMI medium at 106 cells/ml before the co-
incubation. AGS cells were plated in 6-well Plates 24
hours before co-cultivation, then 60 - 70% confluent AGS
cells in 1 ml complete F-12K medium were incubated with
106 induced and washed EBV-LCL cells in 1 ml complete
RPMI. 24 hours later, 2 ml of Serum free F-12K medium
was added to each well to reduce the FBS concentration
to 5% to prevent cell overgrowth. 3 days after co-
incubation, EBV-LCL cells were removed from the co-
cultures and the AGS cells were thoroughly washed with
PBS at least 5 times to remove any of the donor EBV-LCL
cells. The infected AGS cells was then incubated with
fresh F-12K medium with 10% FBS and 100 μg/ml hygro-
mycin B and the selection medium was changed every 2
to 3 days until the infected AGS cells formed Hyg B selec-
tion colonies with GFP expression (usually 3 to 4 weeks
after co-cultivation). The selection colonies were then
pooled and tested for EBNA1 expression and EBV genome
copy number before subject to experiments. AGS-EBV
cells were maintained in F-12K medium with 10% FBS
and 100 μg/ml hygromycin B.
pLU-EBNA1 Lentivirus expression vector was con-
structed by PCR amplification of EBNA1 with primers
(GCGGGATCCTCTGACGAGGGGCCAGGTACAG
GACCT and ATCGTCGACTCACTCCTGCCCTTCCT
CACCCTCATC) introducing a 5′ BamH I and 3′ Sal I
site cloned in frame to pLU-TCMV-FMCS-pPURO. AGS
or MKN74 cells were infected with Lentivirus expressing
pLU-EBNA1 or pLU control vector generated freshly from
293T cells. Infected AGS or MKN74 cells were then
selected with 2.5 μg/ml Puromycin for 10 to 14 days. The
selected cells were pooled and treated with or without 5'-
azacytidine for 48 hours then subjected to RT-PCR.
siRNA against EBNA1 and siRNA Control (Cat. No. D-
001810-01-20) were all purchased from Dharmacon.
siRNA directed against EBNA1 3′UTR were synthesized
using the target sequence CGGAGAUGACGGAGAUG
AAUU. Transfection of siRNA duplexes was conducted by
Lu et al. Virology Journal 2014, 11:12 Page 10 of 11
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turers specifications.
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed as described previously [49].
Quantification of precipitated DNA was determined using
real-time PCR and the delta Ct method for relative quanti-
fication (ABI 7900HT Fast Real-Time PCR System; Ap-
plied Biosystems). Primers for ChIP assays are available
upon request. The following antibodies were used for
ChIP assays: rabbit anti-EBNA1 (305/10 wk), anti- rabbit
IgG (Santa Cruz Biotechnology, sc-2027). Anti-Actin HRP
(Sigma, A3854) and rabbit anti-EBNA1 (305/10 wk) were
used for Western Blotting. EBNA1 specific antibody was
raised against a bacterial EBNA1 protein lacking the GA-
repeat region using New Zealand white rabbits and then
affinity purified using the same bacterial protein coupled
to sepharose beads.
EMSA
DNA fragments were labeled using T4 polynucleotide kin-
ase (NEB) in the presence of [γ-32p]ATP and purified
using G-25 spin columns (GE Healthcare). Purified
EBNA1 DNA binding domain [17] was incubated with
probes at room temperature for 30 min in a total volume
of 20 μl buffer containing 10mM TrisCl PH 8.0, 100 mM
KCl, 1 mM EDTA, 10 mM MgCl2, 0.05 μg/μl poly(dI-dC),
0.5 μg/μl bovine serum albumin, 0.05% NP40, 35 mM β-
mercaptoethanol, and 10% glycerol. The samples were
then separated by electrophoresis on a native 5% polyacry-
mide gel. Gels were dried and analyzed using a Typhoon
phosphorImager system. The forward probe sequences are
gatccggatacagattaggatagcatatactaccca (FR), tttcttattttccagg
cagcatatactatctcaagctcaccatgtc (GKN1/2) and cgccgccgggg
cctgcggcgcctcccgcccgggcatggggccgcgc (negative control,
LANA binding sites at KSHV TR).
Quantitative RT-PCR
For cell lines, RNA was isolated from 2 × 106 cells using
RNeasy Kit (Qiagen) and then further treated with
DNase I. Reverse transcriptase PCR (RT-PCR) was per-
formed as previously described [50]. Real-time PCR was
performed with SYBR green probe in an ABI Prism 7900
according to the manufacturer’s specified parameters.
Primer sequences for RT-PCR are available upon re-
quest. Total human stomach RNA (Cat. No. 540037)
was purchased from Agilent Technologies.Genome copy number assay
Genome copy number assay was performed as de-
scribed previously [51]. The total cellular DNA was
assayed by real-time PCR using primers for the EBV
Ori-Lyt region and normalized by the cellular GAPDHDNA region. The primers for Ori-Lyt and GAPDH are
available upon request.
MeDIP
Methyl-DNA immunoprecipitation (MeDIP) methods have
been described previously [51]. MeDIP DNA were ana-
lyzed by real-time PCR with delta Ct method for quan-
tification. The primers for MeDIP are available upon
request.
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